The New Zealand Commerce Commission has formally launched an investigation into the proposed merger between global consumer giants Kimberly-Clark and Kenvue, raising questions about the future of common household products found in supermarkets across the country.

 

The proposed acquisition, valued globally at nearly $49 billion USD (exceeding $80 billion NZD), aims to unite Kimberly-Clark—the manufacturer of brands such as Kleenex, Huggies, and U by Kotex—with Kenvue, the health-focused owner of Aveeno, Neutrogena, and Band-Aid.

 

While the merger received overwhelming support from shareholders in January, the New Zealand Commerce Commission is now tasked with determining whether the union could "substantially lessen competition" within the local market.

 

The primary point of regulatory contention is the feminine hygiene sector. Both companies currently hold significant market share in New Zealand with competing brands. Kimberly-Clark supplies U by Kotex, while Kenvue owns both Stayfree and Carefree.

 

Regulators are concerned that consolidating these portfolios under a single entity could reduce choices for consumers and potentially drive up prices. To mitigate these concerns and preempt a potential regulatory block, Kimberly-Clark has proposed to divest the entirety of Kenvue’s feminine hygiene product line in Australia and New Zealand.

By selling these brands, Kimberly-Clark effectively aims to preserve the existing competitive landscape, ensuring that Stayfree and Carefree remain in the hands of a competitor rather than being absorbed into their own brand portfolio.

 

The Commission has released a "Statement of Preliminary Issues," outlining the specific factors it will weigh before granting clearance. The regulator is currently inviting feedback from industry stakeholders and the public to determine if the proposed divestment is sufficient to maintain healthy competition.

Interested parties have until March 17, 2026, to submit their views to the Commerce Commission.

 

The Commerce Commission is scheduled to reach a final decision on the application by April 28, 2026. However, this timeline remains subject to change should the Commission require further information or if it determines that the complexity of the divestment package necessitates a more extensive review.

 

The planned takeover is part of a wider global transaction that would create one of the world’s largest consumer health and personal care groups, combining household names in baby care, tissue, skincare and over-the-counter healthcare under a single corporate roof. 

If regulators, including those in New Zealand, grant approval, completion of the deal is expected later this year or in 2027.